Complete paraplegia with diffuse osteolytic skeletal metastases: an uncommon presentation of carcinoma of the prostate.
Journal
Spinal cord series and cases
ISSN: 2058-6124
Titre abrégé: Spinal Cord Ser Cases
Pays: England
ID NLM: 101680856
Informations de publication
Date de publication:
22 04 2020
22 04 2020
Historique:
received:
10
02
2020
accepted:
22
03
2020
revised:
22
03
2020
entrez:
24
4
2020
pubmed:
24
4
2020
medline:
6
8
2021
Statut:
epublish
Résumé
Skeletal metastases of advanced prostatic cancer are usually osteoblastic in appearance. Osteolytic secondaries are an uncommon entity. In such scenarios, it is important to differentiate prostatic metastases from other pathologies which give an identical radiological appearance, such as multiple myeloma. Another important point to remember is that neurological complications secondary to prostatic metastases are quite uncommon. We describe a man with advanced prostatic carcinoma who presented to us with an uncommon combination of sudden onset complete paraplegia associated with diminished sensation in the lower half of the body and diffuse osteolytic lesions in the entire skeletal system. On detailed workup, it was found that his prostatic specific antigen (PSA) was grossly elevated. Markers for multiple myeloma were negative. Accordingly, computerized tomography of the abdomen was performed. The latter revealed an enlarged prostate gland infiltrating into the bladder base. Histopathological analysis from the prostate as well as the bone marrow showed an identical picture thereby confirming our diagnosis. The individual underwent palliative spinal canal decompression following which he was put on anti-androgenic treatment. At one year follow up, he was ambulatory and able to walk with use of crutches. To the best of our knowledge, this is the first reported case of osteolytic prostatic metastases presenting as complete paraplegia. In this situation, in addition to evaluation for prostate CA, we also recommend screening for multiple myeloma as the clinico-radiological profile of the two diseases are similar but their management is very different.
Identifiants
pubmed: 32321926
doi: 10.1038/s41394-020-0276-7
pii: 10.1038/s41394-020-0276-7
pmc: PMC7176645
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25Références
Segamwenge IL, Mgori NK, Yussuf SA, Mukulu CN, Nakangombe P, Ngalyuka PK, et al. Cancer of the prostate presenting with diffuse osteolytic metastatic bone lesions: a case report. J Med Case Rep. 2012;6:425.
doi: 10.1186/1752-1947-6-425
Messiou C, Cook G, deSouza NM. Imaging metastatic bone disease from carcinoma of the prostate. Br J Cancer. 2009;101:1225–32.
doi: 10.1038/sj.bjc.6605334
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide: IARC CancerBase No.10. Int Agency Res Cancer. 2010. http://globocan.iarc.fr .
Langley RR, Fidler IJ. The seed and soil hypothesis revisited - the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. 2011;128:2527–35.
doi: 10.1002/ijc.26031
Rajendiran G, Green L, Chhabra G. A rare presentation of prostate cancer with diffuse osteolytic metastases and PSA of 7242 ng/ml. Int J Case Rep Image. 2011;2:16–20.
doi: 10.5348/ijcri-2011-09-55-CR-5
Vinjamoori AH, Jagannathan JP, Shinagare AB, Taplin ME, Oh WK, Van den Abbeele AD, et al. Atypical metastases from prostate cancer: 10-year experience at a single institution. AJR Am J Roentgenol. 2012;199:367–72.
doi: 10.2214/AJR.11.7533
Idowu BM. Prostate carcinoma presenting with diffuse osteolytic metastases and supraclavicular lymphadenopathy mimicking multiple myeloma. Clin Case Rep. 2018;6:253–7.
doi: 10.1002/ccr3.1336
Alabed YZ. Prostate cancer lytic bone metastases imaged with 18F-Fluorocholine PET/CT. Clin Nucl Med. 2018;43:220.
doi: 10.1097/RLU.0000000000001973
Sharma P, Karunanithi S, Dhull VS, Jain S, Bal C, Kumar R. Prostate cancer with lytic bone metastases: 18F-fluorodeoxyglucose positron emission tomography-computed tomography for diagnosis and monitoring response to medical castration therapy. Indian J Nucl Med. 2013;28:178–9.
doi: 10.4103/0972-3919.119545
Bird VY, Domino PM, Sutkowski R, Stillings SA, Trejo-Lopez JA. Prostate cancer with metastatic lytic bone lesions: positive bone scan post docetaxel chemotherapy in the setting of clinically successful treatment. Urol Case Rep. 2016;6:12–4.
doi: 10.1016/j.eucr.2015.12.008
Migita T, Maeda K, Ogata N. A case of prostate cancer associated with osteolytic bone metastases. Hinyokika Kiyo (Acta Urologica Japanica). 1999;45:371–4. in Japanese.
Agheli A, Patsiornik Y, Chen Y, Chaudhry MR, Gerber H, Wang JC. Prostate carcinoma, presenting with a solitary osteolytic bone lesion to the right hip. Radio Case Rep. 2009;4:288.
doi: 10.2484/rcr.v4i4.288
Ansari MS, Nabi G, Aron M. Solitary radial head metastasis with wrist drop: a rare presentation of metastatic prostate cancer. Urol Int. 2003;70:77–9.
doi: 10.1159/000067696
Bakhsh MU, Lee S, Ahmad S, Takher J, Pareek A, Syed U, et al. Should prostate cancer be considered as a differential diagnosis in patients with osteolytic bone lesions? Eur Rev Med Pharm Sci. 2015;19:4791–4.
Nanda S, Bhatt SP, Steinberg D, Volk SA. Unusual cause of generalized osteolytic vertebral lesions: a case report. J Med Case Rep. 2007;1:33.
doi: 10.1186/1752-1947-1-33
Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T. Surgical strategy for spinal metastases. Spine 2001;26:298–306.
doi: 10.1097/00007632-200102010-00016
Rabbani SA, Gladu J, Harakidas P, Jamison B, Goltzman D. Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo. Int J Cancer. 1999;80:257–64.
doi: 10.1002/(SICI)1097-0215(19990118)80:2<257::AID-IJC15>3.0.CO;2-3
Benjamin R. Neurologic complications of prostate cancer. Am Fam Physician. 2002;65:1834–40.
pubmed: 12018806